Nintedanib


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Idiopathic pulmonary fibrosis
Adult: 150 mg bid. Max: 300 mg daily. Skip the missed dose and wait until the next scheduled dose. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).

Oral
Locally advanced non-small cell lung carcinoma, Locally recurrent non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: In combination with docetaxel: 200 mg bid on days 2 21 of a 21-day treatment cycle. Max: 400 mg daily. Skip the missed dose and wait until the next scheduled dose. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Hepatic Impairment
Oral
Idiopathic pulmonary fibrosis: Mild (Child Pugh A): 100 mg bid, consider treatment interruption, or discontinuation according to individual safety or tolerability (refer to detailed product guideline). Moderate or Severe (Child Pugh B or C): Not recommended.

Locally advanced non-small cell lung carcinoma; Metastatic non-small cell lung carcinoma; Locally recurrent non-small cell lung carcinoma: Moderate or Severe (Child Pugh B or C): Not recommended.
Cách dùng
Should be taken with food. Swallow whole w/ liqd. Do not chew/crush cap because of bitter taste.
Thận trọng
Patient with recent abdominal surgery, history of peptic ulceration, diverticular disease, risk of bleeding, risk factors for liver enzymes elevation, hypertension, high CV risk factors (e.g. coronary artery disease). Smokers. Hepatic impairment. Children. Pregnancy and lactation.
Phản ứng phụ
Significant: Gastrointestinal disorders (e.g. diarrhoea, nausea, vomiting), dehydration, electrolyte disturbance, venous and arterial thromboembolic events (e.g. MI), hypertension, liver enzyme elevation, hyperbilirubinaemia, febrile neutropaenia, sepsis.
Blood and lymphatic system disorders: Thrombocytopaenia, neutropaenia.
Gastrointestinal disorders: Abdominal pain, mucositis, stomatitis.
Hepatobiliary disorders: Increased gamma-glutamyl transferase.
Infections and infestations: Abscess.
Investigations: Weight loss.
Metabolism and nutrition disorders: Decreased appetite.
Nervous system disorders: Headache, peripheral neuropathy.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Gastrointestinal perforation, severe liver injury, non-serious and serious bleeding events.
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Obtain CBC with differential, and pregnancy test prior to initiation and during each cycle of treatment. Monitor LFT and at baseline, monthly during the first 3 months of treatment, and periodically thereafter. Monitor blood pressure, gastrointestinal disturbances, and changes in prothrombin time, INR, and bleeding episodes regularly.
Quá liều
Symptoms: Nasopharyngitis, gastrointestinal symptoms, increased liver enzymes. Management: Supportive treatment.
Tương tác
Increased risk of gastrointestinal adverse effect with corticosteroids and NSAIDs. Increased plasma concentration with strong P-gp inhibitors (e.g. ketoconazole, erythromycin, ciclosporine). Decreased plasma concentration with strong P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin).
Food Interaction
Reduced plasma concentration with St. John’s wort.
Tác dụng
Description: Nintedanib is an inhibitor of multiple receptor tyrosine kinases (RTKs) and nonreceptor tyrosine kinases (nRTKs). It binds competitively to the ATP binding pocket of these receptors and blocks the intracellular signaling which is vital for the proliferation, migration, and transformation of fibroblasts involved in the pathology of pulmonary fibrosis.
Pharmacokinetics:
Absorption: Food, increases exposure and delays absorption. Absolute bioavailability: Approx 5%. Time to peak plasma concentration: 2-4 hours.
Distribution: Volume of distribution: 1,050 L. Plasma protein binding: Approx 98%, mainly to albumin.
Metabolism: Initially metabolised in the liver via hydrolytic cleavage by esterases to a free acid moiety, BIBF 1202, then undergoes glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) enzymes; metabolised by CYP3A4 enzymes (minor).
Excretion: Mainly via faeces (approx 93%); urine (<1%). Terminal elimination half-life: 9-15 hours.
Đặc tính

Chemical Structure Image
Nintedanib

Source: National Center for Biotechnology Information. PubChem Database. Nintedanib, CID=135423438, https://pubchem.ncbi.nlm.nih.gov/compound/Nintedanib (accessed on Jan. 22, 2020)

Bảo quản
Store at 25°C. Protect from heat and moisture.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, administration and disposal. Any unused portions should be disposed of in accordance with local requirements.
Phân loại ATC
L01XE31 - nintedanib ; Belongs to the class of protein kinase inhibitors, other antineoplastic agents. Used in the treatment of cancer and other indications.
References
Anon. Nintedanib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/03/2018.

Buckingham R (ed). Nintedanib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2018.

Joint Formulary Committee. Nintedanib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2018.

Ofev Capsule (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/03/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Nintedanib từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in